Publications

Rigorous science with demonstrated consistent outcome:

  • Di Pasqua AJ, Huckle JE, Kim JK, Chung Y, Wang AZ, Jay M and Lu X. Preparation of neutron activatable holmium nanoparticles for the treatment of ovarian cancer metastases. Small. 2012, 8 (7): 997-1000

  • Di Pasqua AJ, Miller ML, Lu X, Peng L, Jay M., Tumor accumulation of neutron activatable holmium-containing mesoporous silica nanoparticles in an orthotopic non-small cell lung cancer mouse model, Inorganica Chimica Acta. 2012, 393: 334–336

  • Di Pasqua AJ, Yuan H, Chung Y, Kim JK, Huckle JE, Li C, Sadgrove M, Tran TH, Jay M, Lu X. Neutron-activatable holmium-containing mesoporous silica nanoparticles as a potential radionuclide therapeutic agent for ovarian cancer. Journal of Nuclear Medicine. 2013, 54:111-116

  • Fu Q, Hargrove D, Lu X.  Improving Paclitaxel Pharmacokinetics by Using Tumor-Specific Mesoporous Silica nanoparticles with Intraperitoneal Delivery. Nanomedicine: Nanotechnology, Biology, and Medicine. 2016, 12: 1951–1959.

  • Kim J, Narayan R, Lu X, Jay M. Neutron-Activatable Needles for Radionuclide Therapy of Solid Tumors. Journal of Biomedical Materials Research Part A. 2017,105(12):3273-3280

  • Kim J, Luo ZX, Wu Y, Lu X, Jay M. In-situ formation of holmium oxide in pores of Mesoporous Carbon Nanoparticles as substrates for neutron-activatable radiotherapeutics . Carbon. 2017, 117: 92–99.

  • Kashfi-Sadabad R, Gonzalez-Fajardo L, Hargrove D, Ahmadi B, Munteanu D, Shahbazmohamadi S, Jay M and Lu X. Engineering multi-functional gold decorated dendritic mesoporous silica/tantalum oxide nanoparticles for intraperitoneal tumor-specific delivery. Particle and Particle Characterization. 2019, 36 (4):1-10

  • D Hargrove, B Liang, R Kashfi-Sadabadi, G N. Joshi, L Gonzalez-Fajardo, S Glass, M Jay, A Salner, X Lu. Tumor-mesoporous silica nanoparticle Interactions Following Intrapritoneal Delivery for Targeting Peritoneal Metastasis. Journal of Controlled Release. 2020 Dec 10;328:846-858

Awards

  • National Institutes of Health (NIH) National Cancer Institute (NCI) STTR Phase I Award

    “Study section has recognized that this is a very significant effort as ovarian cancer is the second most common gynecologic cancer in the United States and new treatment options are needed”.

    - Grant Review Comments

  • National Institutes of Health (NIH) National Cancer Institute (NCI) SBIR Phase II Award

    " The significance is recognized to be high to develop a treatment that is tumor-specific and further reduces side effects” and “the further development of the technology has potential impact to greatly enhance patient outcomes”

    - Grant Review Comments

  • American Cancer Society

    American Cancer Society

    “It is rare to see a drug delivery grant proposal that could actually lead to a clinical treatment, and this is one of them”.

    - Grant Review Comments

FCOI Policy